IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual Meeting
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021.
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
Telix Establishes Commercial Hub in Geneva, Switzerland
Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH.
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
Telix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
Telix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September 2021.
NCCN Guidelines Updated to Include PSMA-PET Imaging
Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68 PSMA-11.
FDA Approves Phase II Kidney Cancer Therapy Study
Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy, TLX250.
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product Illuccix®
Telix In-Licences Novel Tumour Microenvironment PET Tracer
Telix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de Louvain.